Begin with one evidence question and a traceable literature-to-analysis workflow. Automate repetitive work while preserving clinical, statistical and ethics decisions for qualified reviewers.
Academic research groups, evidence teams and nonprofit trial sponsors.
First product
A cited evidence map, structured extraction sheet and reproducible analysis for one tightly scoped question.
Next decision
The question and review protocol are accepted by a clinical reviewer and statistician.
Product boundary
Automating evidence operations does not clinically validate a treatment. Trial conduct, consent, safety monitoring and regulatory decisions require accountable organisations and experts.
PRODUCT 0 → 1.0
The Phase 0–5 strategy.
Each phase has a concrete deliverable and an acceptance gate. These are proposed development plans, not completed scientific or product validations.
PHASE 0 / 0% MILESTONECurrent planning
Define the evidence question
Choose a question that can be answered with accessible evidence.
Work to do
Specify population, intervention, comparator and outcomes with a reviewer.
Define eligible evidence and the limits of available data.
Set a baseline for review time and extraction quality.
Acceptance gate
The question and review protocol are accepted by a clinical reviewer and statistician.
Publish: Question specification and evaluation rubric.
PHASE 1 / 20% MILESTONEPlanned
Create the source pipeline
Make every extracted claim traceable to its origin.
Work to do
Import lawful literature metadata and trial-registry records.
Store identifiers, retrieval dates and source versions.
Build a manually reviewed extraction reference set.
Acceptance gate
Each reference claim links to supporting text; inaccessible content is marked rather than invented.
Publish: Evidence schema and annotated reference set.
PHASE 2 / 40% MILESTONEPlanned
Build the review prototype
Connect screening, extraction and analysis into one inspectable workflow.
Work to do
Add reviewer queues and disagreement resolution.
Generate protocol drafts with explicit assumptions and gaps.
Run an analysis on public or synthetic data with fixed inputs.
Acceptance gate
A reviewer can trace each report statement to evidence and reproduce the analysis.
Publish: Evidence workspace prototype and example report.
PHASE 3 / 60% MILESTONEPlanned
Evaluate accuracy and bias
Measure performance on evidence the system has not already seen.
Work to do
Compare extraction and screening with independent human review.
Measure unsupported citations, omissions and disagreement rates.
Test study overlap, missing outcomes and sensitivity to selection choices.
Acceptance gate
Predefined quality thresholds pass on held-out questions; failures and uncertainty remain visible.
Publish: Evaluation report and reproducibility bundle.
PHASE 4 / 80% MILESTONEPlanned
Pilot with a research team
Test the workflow in a supervised evidence project.
Work to do
Assign named clinical and statistical reviewers.
Compare total reviewer effort and corrections against the baseline.
Document what still requires manual judgment.
Acceptance gate
The team completes the agreed evidence task with an auditable review record.
Publish: Partner pilot report and reviewer feedback.
PHASE 5 / 100% MILESTONEPlanned
Release the evidence workspace
Support repeatable evidence operations within a defined scope.
Work to do
Publish versioned exports, access roles and audit-log behaviour.
Document verification, retention and incident handling.
Release only the evidence workflows that passed evaluation.
Progress stays at 0% until the starting scope is accepted and subsequent milestone evidence is published. Phase 1–5 targets are 20%, 40%, 60%, 80% and 100%. These percentages track development, not treatment effectiveness.
WHAT THIS DEPENDS ON
Build with the right foundations.
Datasets & models library: lawful sources and frozen evidence snapshots.
Clinical reviewer and statistician: question design, extraction and analysis review.
Research sponsor and ethics expertise before any prospective study.
Partner roles above are requirements. No partner participation or endorsement is claimed.
FUTURE INTERACTIVE PRODUCT
Evidence project workspace
Open an evidence-only pilot after citation and extraction checks pass. Patient data and trial operations require a separate approved implementation.
Register the question and search strategy.
Screen and extract with reviewer disagreements visible.
Lock the analysis plan and run a reproducible pipeline.
Published the module strategy, concrete phase deliverables, acceptance criteria and future portal workflow. This is a planning update; product completion remains 0%.
Entries are published with site updates. Planned work is labelled separately from completed product milestones.